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Introduction 
 
Prostate cancer is the most common male can-
cer in Western countries, including Europe, 
North America and parts of Africa [1]. Despite 
extensive studies and certain achievements in 
this disease, many issues still remain regarding 
the management and treatment of prostate 
cancer. Prostate cancer has a natural course 
that is different from many other human tu-
mours. Most early-stage prostate cancers are 
latent and only approximately 25% of them will 
become aggressive and life-threatening [2]. 
However, currently, it is difficult to differentiate 
between low- and high-risk localised prostate 
cancers [2-4]. Following the application of the 
prostate-specific antigen (PSA) test for early 
detection of prostate cancers, there is a big is-
sue in managing these early stage cancers. It is 
a dilemma to treat early-stage localised can-
cers. The current methods commonly used in 
the US and many other countries may over-treat 
the majority of early prostate cancer patients 
who will not develop metastases. However, con-
servative management, such as watchful wait-
ing and active surveillance, which is used in 
certain European countries may miss the oppor-
tunity to cure the small proportion of aggressive 
disease at an early stage [3]. Once aggressive 
cancer has progressed to the metastatic stage, 
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Abstract:  Prostate cancer, the most common male cancer in Western countries, is commonly detected with complex 
chromosomal rearrangements. Following the discovery of the recurrent TMPRSS2:ETS fusions in prostate cancer and 
EML4:ALK in non-small-cell lung cancer, it is now accepted that fusion genes not only are the hallmark of haemato-
logical malignancies and sarcomas, but also play an important role in epithelial cell carcinogenesis. However, previ-
ous studies aiming to identify fusion genes in prostate cancer were mainly focused on expression changes and fusion 
transcripts. To investigate the genes recurrently affected by the chromosome breakpoints in prostate cancer, we ana-
lysed Affymetrix array 6.0 and 500K SNP microarray data from 77 prostate cancer samples. While the two genes 
most frequently affected by genomic breakpoints were, as expected, ERG and TMPRSS2, surprisingly more known 
tumour suppressor genes  (TSGs) than known oncogenes were identified at recurrent chromosome breakpoints. Cer-
tain well-characterised TSGs, including p53, PTEN, BRCA1 and BRCA2 are recurrently truncated as a result of chro-
mosome rearrangements in prostate cancer. Interestingly, many of the genes residing at recurrent breakpoint sites 
have not yet been implicated in prostate carcinogenesis such as HOOK3, PPP2R2A and TCBA1. We have confirmed 
the generally reduced expression of selected genes in clinical samples using quantitative RT-PCR analysis. Subse-
quently, we further investigated the genes associated with the t(4:6) translocation in LNCaP cells and reveal the ge-
nomic fusion of SNX9 and putative TSG UNC5C, which led to the reduced expression of both genes. This study re-
veals another common mechanism that leads to the inactivation of TSGs in prostate cancer and the identification of 
multiple TSGs inactivated by chromosome rearrangements will lead to new direction of research for the molecular 
basis of prostate carcinogenesis. 
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the chance of survival is low. The treatment 
strategy for metastatic prostate cancer is andro-
gen deprivation. Although this treatment works 
efficiently in the majority of patients, most can-
cers usually relapse after two years [4, 5]. When 
the disease becomes androgen-resistant, very 
limited options are left [4]. Chemotherapy for 
prostate cancer is generally unsuccessful, al-
though recently new developments have been 
achieved [5]. Therefore, currently, advanced 
disease is still incurable and it is difficult to pre-
dict the progression of early stage cancers [2-5]. 
 
Cancer is a genetic disease. Chromosome rear-
rangements, including translocations, inver-
sions and internal deletions are the hallmarks 
of human cancer [6]. Fusion genes and the de-
regulation of oncogenes associated with chro-
mosome rearrangement have been extensively 
studied in haematological malignancies and 
soft tissue sarcomas and can frequently be 
used to define a tumour subtype and are associ-
ated with disease prognosis [6]. Gleevec (also 
known as Imatinib or STI571), which targets the 
BCR:ABL gene fusion product in chronic myeloid 
leukaemia, was the first successful drug devel-
oped for gene-targeted therapy [7]. Carcinomas 
are the most common human malignancies. 
However, due to the complexity of the genomic 
alterations in cells from carcinomas and the 
difficulty in karyotyping them, only a small num-
ber of fusion genes, each occurring at a low 
frequency, have been reported in tumours of 
epithelial origin. Until recently, many people 
believed that gene fusions were not important 
events in carcinomas [8]. Following the recent 
discovery of recurrent fusions of the TMPRSS2 
and ETS family transcription factor genes in 
prostate cancer [9-11] and EML4:ALK in non-
small-cell lung cancer [12], it is now accepted 
that fusion genes also play an important role in 
epithelial cell carcinogenesis [6].  
 
Although detected at a much higher frequency 
in certain types or subtypes of human malignan-
cies, the fusion genes previously identified in 
haematological malignancies and sarcomas, 
occur only in relatively rare tumour types. Due to 
the high incidence of prostate cancer, 
TMPRSS2:ERG, which occurs in about 50% of 
prostate cancer, is currently the most frequently 
found fusion gene in human malignancies [6]. 
The discovery of the high frequency TMPRSS2 
and ETS fusion has stimulated huge interest in 
the search to find more fusion genes and inves-
tigation into their roles in carcinomas, particu-
larly in prostate cancer. However, apart from the 
fusion of ETS family genes with TMPRSS2 and 
other genes highly active in prostate epithelial 
cells, including SLC45A3, HERV-K_22q11.23, 
C15orf21 and HNRPA2B1 [9, 13-15], no other 
frequent fusion genes have been found in pros-
tate cancer, so far [13-16].  
 
Prostate cancer is commonly detected with very 
complex chromosome rearrangements involving 
many chromosome breakpoints and rejoins [17, 
18], the majority of which are unbalanced. It is 
now clear that unbalanced chromosome trans-
locations can also affect the genes located at or 
close to chromosome breakpoints [19]. As it is 
difficult to culture primary prostate cancer cells 
for karyotyping analysis, new approaches have 
to be explored to identify genes that are recur-
rently affected by chromosome rearrangements. 
The expression outlier analysis was successfully 
used to identify the common TMPRSS:ETS fu-
sions [9-11]. The development of next genera-
tion sequencing technology has provided better 
resolution to detect genetic alterations and has 
recently been applied for transcriptome se-
quencing [13-16]. However, it is not necessarily 
the case that all chromosome rearrangements 
result in fusion transcripts and/or over-
expression of affected genes. Therefore, fusion 
events that do not result in fusion transcripts or 
significantly increased level of expression would 
remain undetected using these approaches 
focusing on expression level changes. Recently, 
next-generation sequencing was also applied to 
whole genomes and many genomic rearrange-
ments have been identified at the DNA base 
pair level [20]. It is currently still very expensive 
to sequence the entire genome and analysis of 
the vast amount of complicated genomic data is 
challenging. Therefore, only seven prostate can-
cer samples were analysed in the recent report 
[20], which is impossible to assess the fre-
quency of genes affected. High-density genomic 
microarrays provide good coverage of the hu-
man genome allowing breakpoints (seen as 
boundary of DNA copy number changes) to be 
determined at a sufficiently high resolution (an 
average of a few kb per SNP). A vast amount of 
microarray genomic copy number change data 
already exists and it is simple to identify the 
genes truncated by chromosome rearrange-
ments- genes located at the genomic gain and 
loss breakpoints. This offers an opportunity to 
rapidly identify genes that are frequently trun-
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cated by the chromosome rearrangements.  
 
To investigate the genes recurrently affected by 
the chromosome breakpoints in prostate can-
cer, we analysed Affymetrix array 6.0 and 500K 
SNP microarray data for genes located at ge-
nomic copy number change breakpoints. We 
revealed that many tumour suppressor genes 
(TSGs) are recurrently truncated as a result of 
chromosome rearrangements in prostate can-
cer. Subsequently, we further investigated the 
inactivation of genes associated with the t(4:6) 
in LNCaP prostate cancer cell line. 
 
Material and methods 
 
Cell lines 
 
Six prostate cancer cell lines (PC3, DU145, 
LNCaP, VCaP, 22RV1 and MDAPCa2b) were 
used in this study. All cell lines were obtained 
from American Type Culture Collection (ATCC).  
 
Fresh frozen prostate clinical samples 
 
32 UK and 39 Chinese prostate cancer radical 
prostatectomy samples were collected, snap 
frozen and stored in liquid nitrogen at local tis-
sue banks. Gleason grading and the percentage 
of tumour cells in each sample were reviewed 
using H&E stained frozen sections. Local re-
search ethics committees have approved the 
use of clinical samples for this study. 
 
Nucleic acid extraction 
 
For DNA extraction, cancer, high-grade prostate 
intraepithelial neoplasia (HGPIN) and adjacent 
normal tissue from fresh frozen sections were 
macro- or micro-dissected to achieve >70% pu-
rity of cancer cells. For RNA extraction, only 
cases suitable for macrodissection were used to 
increase the purity of cancer cells. DNA and 
RNA extraction from cell lines were performed 
following standard protocols. Fresh frozen tis-
sue was cut into 5 µm sections using 
Cryotome® E electronic cryostat.  
 
Microarray analysis 
 
Microarray data for 3 prostate cancer cell lines 
and 44 clinical prostate cancer samples have 
been published previously [17, 21]. In combina-
tion with array data from a further 3 prostate 
cancer cell lines and 27 clinical prostate sam-
ples, we analysed all SNP array data (SNP 6.0 
and 500K) to identify genes recurrently trun-
cated by chromosome breakpoints. The in-
house developed software program, GOLF [21, 
22], was used to display the intensity of SNPs 
along each chromosome and genomic break-
points were identified where the intensity of 
SNP signals changed if the signal intensity ratio 
of the mean of 20 contiguous probes differs 0.4 
log2 ratio for two adjacent SNP blocks. Probes 
were mapped using Ensembl genome build 
hg18. 
 
Quantitative reverse transcription PCR (QRT-
PCR) gene expression analysis 
 
Total RNA was reverse transcribed using Super-
script II (Invitrogen) following the manufacturers 
instructions. QRT-PCR was performed using the 
ABI Prism 7700 Sequence Detector (Applied 
Biosystems, Foster City, CA) keeping the default 
settings for baselines and thresholds. Pre-
designed Taqman® gene expression assays 
were purchased from Applied Biosystems. Spe-
cific probes are outlined in Table 1. 40 ng cDNA 
was used for each PCR reaction and each sam-
ple was performed in triplicate. Endogenously 
expressed GAPDH was used as an internal con-
trol.  
 
Fluorescence in situ hybridisation (FISH) analy-
sis 
 
FISH on metaphase slides was carried out using 
standard protocols. Six BAC clones (RP11-
Table 1. Taqman QRT-PCR probes 
Gene Probe ID Chr. Chr. Location Exon Boundary Amplicon Length (bp) 
UNC5C Hs01031779_m1 4 96083655 - 96470361 9-10 81 
SNX9 Hs00212006_m1 6 158244294 - 158366109 2-3 88 
PPP2R2A Hs00160392_m1 8 26149007 - 26230196 1-2 92 
HOOK3 Hs00260887_m1 8 42752033 - 42885682 13-14 81 
WWOX Hs03044790_m1 16 78133551 - 79246564 4-5 89 
GAPDH Hs99999905_m1 12 6643657 - 6647536 3-3 122 
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160A16 at proximal 4q22.3, RP11-240J11 at 
distal 4q22.3, RP11-111J1 at proximal 6q15, 
RP11-337M11 at distal 6q15, RP3-481C9 at 
proximal 6q25.3 and RP1-249F5 at distal 
6q25.3) were obtained from the Welcome Trust 
Sanger Institute (Hinxton Hall, Cambridge, UK). 
BAC DNA was extracted using Qiagen-Tip 
method following the manufacture suggested 
protocols. BAC DNA was then labelled directly 
with fluorescent dyes using a nick-translation 
method as described previously [23]. RP11-
160A16, RP11-240J11 and RP1-249F5 were 
labelled by Cy5 and RP11-111J1, RP11-
337M11 and RP3-481C9 were labelled with 
Cy3. All labelled probes were cleaned up by G50 
columns and precipitated by vacuum drier.  
 
Metaphase slides were prepared from cell lines 
using standard cytogenetic methods and stored 
at -20oC. Before hybridisation, slides were pre-
treated with 70% acetic acid for 10 min and 
neutralised by PBS washes. Metaphase slides 
and labelled BAC probes re-suspended in hy-
bridisation buffer (2xSSC, 10% dextran sul-
phate, 50% formamide, 1% Tween 20, pH 7) 
were denatured separately. 10 µl of hybridisa-
tion solution containing 200 ng of each labelled 
BAC probe was applied onto the denatured slide 
and covered with a 22X22 mm coverslip. Hy-
bridisation was performed at 37oC over-night 
and then slides were washed using standard 
formamide wash protocol. Finally, 20 μl Vec-
tashield antifade solution (containing DAPI) was 
added to each slide after dehydration and 
mounted with coverslips. FISH signals were re-
viewed and captured using an Olympus fluores-
cent microscope equipped with a CCD camera 
and red/green/blue three-colour filter wheel, 
controlled by a computer using MacProbe 4.3 
software (Applied Imaging, CA).  
 
Results 
 
Identification of recurrent breakpoint in pros-
tate cancer and the associated genes by SNP 
array analysis 
 
In this study, SNP array data from 71 clinical 
prostate cancer cases and 6 prostate cancer 
cell lines were manually analysed with our in-
house software, GOLF, and 41 recurrent break-
points (n≥2) were detected within putative 
TSGs, oncogenes and/or genes previously iden-
tified as a partner gene in gene fusion events 
(Table 2). As expected, the two most frequent 
breakpoints identified resided on chromosome 
21, where the ERG and TMPRSS2 gene are lo-
cated (18/77 and 15/77 cases, respectively). 
The HOOK3 gene was also found at the break-
points at a considerably high frequency (7/77). 
Surprisingly, this breakpoint analysis of microar-
ray data revealed preferential involvement of 
TSGs (n=27) as compared to oncogenes (n=6). 
Four of the identified TSGs, PPP2R2A, ETV6, 
WWOX and BRCA1, occurred at the breakpoints 
in at least 4 samples. Representative array im-
ages are shown in Figure 1. The well-
characterised TSGs p53, PTEN and BRCA2 were 
also found at recurrent breakpoints of copy 
number changes. Twenty of the genes located 
on the recurrent breakpoints have previously 
been reported as fusion partner genes. 
 
From the list of genes recurrently located on the 
breakpoints, we investigated the expression 
level of three genes, HOOK3, PPP2R2A and 
WWOX using QRT-PCR. HOOK3 expression var-
ies slightly in non-malignant prostate epithelial 
cells and is downregulated in 7 prostate cancer 
or HGPIN samples as compared to their 
matched normal controls (Figure 2A). In one 
paired tumour and normal and one paired 
HGPIN and normal comparison, HOOK3 expres-
sion was lower in the normal cells. In 8 of 9 
paired samples analysed, PPP2R2A expression 
was reduced in tumour samples as compared to 
their case-matched normal controls (Figure 2B). 
Unfortunately, none of the paired samples avail-
able for QRT-PCR analysis were from cases 
where genomic breakpoints in the PPP2R2A 
had been identified by SNP array analysis. 
WWOX gene expression was also reduced in the 
tumour/HGPIN lesions from 8 of 9 paired sam-
ples. However, the only sample (WX94) ana-
lysed by QRT-PCR where a genomic breakpoint 
was detected in the WWOX gene by SNP array 
analysis, showed higher WWOX expression in 
the tumour sample than the normal (Figure 2C).  
 
Characterisation of the t(4;6) in LNCaP and the 
downregulation of UNC5C and SNX9 expression  
 
We further investigated the previously identified 
t(4;6) translocation [24] and its impact on 
genes located at the breakpoints. From our ar-
ray data, while only one deletion occurred on 
chromosome 4 (4q22.3: 158,266-160,264 kb) 
(Figure 3A), two deletions occurred on chromo-
some 6q (6q15: 87,631-91,744 kb and 
6q25.3: 158,266-160,264 kb). This correlated 
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to the two translocation breakpoints on chromo-
some 6 and one translocation breakpoint on 
chromosome 4 in the t(4;6) chromosome trans-
location revealed by multiplex fluorescent in situ 
hybridisation (M-FISH) karyotyping (Figure 3C). 
FISH co-localisation analysis of chromosome 4 
and 6 probes flanking the translocation break-
points was performed to confirm the t(4;6) chro-
mosome rearrangement. Using a distal 4q22.3 
and proximal 6q15 probe we observed co-
localisation on der(6)t(4;6) (Figure 4A). How-
ever, proximal 4q22.3 and distal 6q15 did not 
co-localise on der(4)t(4;6). The latter probe hy-
bridisation signal was located sub-telomerically, 
far away from the 4q22.3 probe (Figure 4B). 
This revealed an inverted configuration of the 
Table 2. Recurrent TSGs, oncogenes and fusion partner genes found in prostate cancer SNP array 
breakpoint analysis 
Gene Chr Start End Samples 
(n=77) 
TSG Oncogene Known fusion 
partner 
ERG 21 38673819 38955488 18   √ √ 
TMPRSS2 21 41758351 41801948 15     √ 
HOOK3 8 42871190 42994084 7   √ √ 
TCBA1 6 124166985 125188502 5     √ 
PPP2R2A 8 25098204 26284562 5 √   √ 
SMAD2 18 43613464 43711510 5 √     
ETV6 12 11694055 11939588 4 √   √ 
WWOX 16 76691052 77803532 4 √     
BRCA1 17 38449840 38530994 4 √     
ARSF X 2969512 3040767 4   √   
LRP1B 2 140705468 142604768 3 √     
ROBO2 3 76069335 77779351 3 √     
SMAP1 6 71434200 71628435 3     √ 
NRG1 8 31617043 32741608 3 √ √ √ 
PTEN 10 89613175 89718511 3 √     
BRCA2 13 31787617 31871809 3 √     
GPC6 13 92677711 93853948 3     √ 
CDH11 16 63535157 63713440 3 √   √ 
P53 17 7512464 7531642 3 √     
DISC1 1 229829184 230243637 2     √ 
RARB 3 25190893 25614424 2 √     
GOLGA4 3 37259742 37383240 2     √ 
LSAMP 3 117011853 117646568 2 √     
SMARCAD1 4 95348217 95431462 2 √     
MSH3 5 79986050 80208387 2 √     
BAI3 6 69401980 70156124 2 √     
CNTNAP2 7 145444902 147749019 2 √   √ 
DLC1 8 12985243 13416766 2 √     
IKBKB 8 42247986 42309122 2   √ √ 
PRKDC 8 48848222 49035296 2 √     
PAG1 8 82042605 82186858 2 √     
ZFPM2 8 106400323 106885939 2     √ 
PTPRD 9 8304246 9008735 2 √     
OPCML 11 131790085 132907429 2 √     
PIK3C2G 12 18305741 18692617 2     √ 
RAD51L1 14 67356262 68187315 2 √   √ 
MKL2 16 14072697 14268130 2     √ 
ADAMTS18 16 75873527 76026512 2 √     
ACCN1 17 28364221 29507664 2 √   √ 
SETBP1 18 40514861 40898771 2     √ 
PTPN1 20 48560298 48634495 2 √ √   
PARVB 22 42726424 42896434 2 √     
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6q15-25.3 fragments in the der(4)t(4;6;10) 
where the proximal breakpoint of 6q25.3 was 
fused to 4q22.3 on der(4)t(4;6) and the 6q15 
breakpoint was fused to chromosome 10. This 
was further confirmed by FISH analysis using 
proximal 4q22.3 and proximal 6q35.3 probes 
(data not shown). The small telomeric 6q region 
had translocated to 10q, which was confirmed 
by FISH analysis using BAC RP1-249F5 located 
at distal 6q25.3 breakpoint (data not shown). 
Fusion of 4q22.3 and 6q25.3 results in the fu-
sion of SNX9 and UNC5C in the same orienta-
tion. However, using various pairs of primers to 
PCR amplify the potential UNC5C:SNX9 fusion 
gene, no PCR product was detected. Using QRT-
PCR, we further investigated 
the expression level of UNC5C 
and SNX9. Both SNX9 and 
UNC5C were expressed at a 
relatively low level in LNCaP 
cells compared to the other 
cell lines (Figure 5). Analysis of 
UNC5C and SNX9 expression 
in clinical prostate cancer 
samples revealed that in most 
cases both genes were down-
regulated in tumour samples 
as compared to their adjacent 
morphologically normal epithe-
lial cells (Figure 5). All cell 
lines analysed expressed low 
level of the two genes, com-
pared to the clinical samples. 
 
Discussion 
 
Recent studies of genomic 
rearrangements in prostate 
cancer have been successful 
in identifying fusion genes, 
particularly the TMPRSS2:ERG 
fusion, which is detected in 
half of prostate cancer sam-
ples and is the most com-
monly found fusion in human 
malignancies [6]. However, the 
approaches used, including 
expression outlier and next 
generation transcriptome se-
quencing, have mainly focused 
on the identification of fusion 
transcripts. It is now evident 
that genomic rearrangements 
have consequences other than 
gene fusion or deregulation of 
oncogenes, such as inactivation of TSGs [6]. 
The complex genomic rearrangements observed 
in prostate cancer may affect the function of 
many TSGs. As inactivation of TSGs by genomic 
rearrangements will not result in fusion tran-
scripts or over-expression of the affected genes, 
genomic analyses may be necessary to reveal 
the TSGs affected by these rearrangements.  
 
Not surprisingly, from our microarray analysis 
the two genes most frequently affected by ge-
nomic breakpoints are the ERG and TMPRSS2 
genes. Fusion events, caused by translocation 
or deletion of the intervening DNA between the 
Chromosome 21 TMPRSS2 and ERG genes, are 
Figure 1. Representative SNP array profiles to show the recurrent genomic 
breakpoints at gene loci. A. Breakpoints at HOOK3 gene. B. Breakpoints in 
TCBA1 gene. C. Breakpoints at WWOX gene. 
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found in approximately 50% of prostate cancer 
cases [21, 25]. The frequency of TMPRSS2 and 
ERG breakpoints observed in our sample set is 
lower than the recorded frequency. This is be-
cause our sample set consists of clinical sam-
ples taken from both Chinese and UK prostate 
cancer patients. We have recently reported that 
the deletions of chromosome 21 (causing 
TMPRSS2:ERG) and 10q (inactivating PTEN), 
which have been reported as frequent events in 
prostate cancer, are detected 
far less frequently in the Chi-
nese population [21].  
 
Interestingly, many of the other 
genes residing at sites of recur-
rent breakpoints have not yet 
been implicated in prostate 
carcinogenesis, such as 
HOOK3, PPP2R2A and TCBA1. 
These genes, which have previ-
ously been characterised as 
gene fusion partners, should be 
further investigated and some 
of them may be novel gene-
fusion partners in prostate can-
cer. Genomic breakpoints 
within the HOOK3 gene were 
found at a considerably high 
frequency (7 cases). QRT-PCR 
analysis using primers span-
ning exon 13-14 showed that 
HOOK3 is down-regulated in 
clinical prostate cancer cases 
as compared to their matched 
normal controls. In a case of 
papillary thyroid carcinoma, a 
fusion product was identified 
between exon 11 of HOOK3 
and exon 12 of the RET gene 
[26]. HOOK3 provides an active 
promoter to drive the expres-
sion of the tyrosine kinase do-
main of RET, thereby rendering 
the HOOK3:RET fusion product 
with oncogenic properties. We 
speculate that truncation of the 
HOOK3 in prostate cancer may 
have the same consequence. 
However, it is also possible that 
decreased gene expression 
may result in reduced activity of 
HOOK3. Further investigation is 
required to identify its fusion 
partner and active role in pros-
tate cancer development or progression.  
 
During this microarray analysis we identified 
many known or putative TSGs located at recur-
rent genomic rearrangement breakpoints. To 
our surprise, we found more known/putative 
TSGs residing at breakpoints than known/
putative oncogenes. Although many recurrent 
breakpoints were identified that do not harbour 
genes with known TSG/oncogene roles, the 
Figure 2. Decreased expression of HOOK3, PPP2R2A and WWOX genes in 
prostate cancer and HGPIN samples detected by QRT-PCR analysis. A. 
HOOK3 gene; B. PPP2R2A gene and C. WWOX gene. P80BPH and P81BPH 
are macrodissected samples from benign prostate hyperplasia cases. N: 
macrodissected morphologically normal gland regions; T: macrodissected 
cancer lesions.  
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Figure 3. Association of one breakpoint on 4q and two breakpoints on 6q with small chromosome deletions revealed 
by SNP array analysis. A. SNP array data show one small deletion on 4q. B. SNP array data show two small deletions 
on 6q. C. The der(4)t(4;6;10) chromosomes from a M-FISH metaphase show one breakpoint on 4q and two break-
points on 6q. 
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large bias towards TSGs, as com-
pared to oncogenes (27:6), indi-
cates that further clarification of 
the genes at recurrent breakpoints 
would not reverse this general 
trend. Chromosome loss, mutation 
and promoter methylation are 
mechanisms that frequently lead 
to TSG inactivation. Now, chromo-
some rearrangements and translo-
cations have been found as an-
other potential common cause of 
TSG inactivation in prostate can-
cer. 
 
In five cases, breakpoints were 
identified in the PPP2R2A gene, 
which is located at the frequently 
deleted chromosome region, 
Figure 4. Representative FISH images showing the fusion of distal 4q22.3 and proximal 6q15 but not proximal 
4q22.3 and distal 6q15 in the t(4;6) of LNCaP cells. A. Hybridisation of clones RP11-240J11 (distal 4q22, green) and 
RP11-111J1 (proximal 6q15, red) to LNCaP cells. The co-localised RP11-240J11 and RP11-111J1 signals on the der
(6) are indicated by an arrow. B. Hybridisation of clones RP11-160A16 (proximal 4q22, green) and RP11-337M11 
(distal 6q15, red) to LNCaP cells. The RP11-160A16 and RP11-337M11 signals located far away on the der(4) are 
indicated by arrows. 
Figure 5. Decreased expression of 
UNC5C and SNX9 genes in prostate can-
cer cell lines, clinical cancer and HGPIN 
samples detected by QRT-PCR analysis. 
A. UNC5C gene and B. SNX9 gene. 
P80BPH and P81BPH are macrodis-
sected samples from benign prostate 
hyperplasia cases. N: macrodissected 
morphologically normal gland regions; T: 
macrodissected cancer lesions. 
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8p21.2. PPP2R2A is a putative TSG that in-
duces apoptosis [27, 28]. Like many of the 
other genes identified at frequent breakpoints, 
PPP2R2A has been identified as a fusion part-
ner gene [29]. Fusion of the PPP2R2A and 
CHEK2 genes, resulting in the balanced chro-
mosome translocation t(8;22)(p21;q12), was 
found in an intrathoracic mature teratoma [29]. 
The PPP2R2A:CHEK2 fusion transcript does not 
result in an in-frame chimeric open reading 
frame, but the open reading frame of the TSG 
CHEK2 is maintained, suggesting that promoter 
swapping leads to deregulated CHEK2 expres-
sion. In this case, the function of both genes 
with tumour suppressor roles was disrupted.  
Using QRT-PCR, we show that in 8 of 9 paired 
samples analysed, PPP2R2A expression was 
reduced in tumour samples as compared to 
their case-matched normal controls. These sug-
gest that PPP2R2A may play a tumour suppres-
sor role in prostate cancer and it is frequently 
inactivated by various mechanisms including 
gene truncation.  
 
In five cases, breakpoints were found within the 
TCBA1 gene at 6q22.31. Deletions of 6q are 
frequently found in human cancers, including 
prostate cancer, acute lymphoblastic leukaemia 
and non-Hodgkin’s B-cell lymphomas [30-32]. 
Tagawa et al found that TCBA1 was involved in 
6q aberrations in both T-cell lymphoma and 
leukaemia cell lines [33]. In a T-cell lymphoblas-
tic lymphoma cell line, HT-1, TCBA1 was found 
fused to SUSP1 (SUMO-1-specific protease), 
creating a SUSP1:TCBA1 chimeric gene, the 
function of which is not yet known [33]. Translo-
cations t(1;6)(q32.3;q22.3) and t(2;6)
(q24.3;q22.31) resulting in constitutional inacti-
vation of the TCBA1 gene have also been de-
tected and are associated with developmental 
delay [34] and neurological disorders [35.]. 
These data support that TCBA1, which was 
found frequently inactivated by deletion or chro-
mosome translocation, may be a candidate TSG 
in prostate cancer. The consequence of the 
truncation of TCBA1 in prostate cancer should 
be further investigated. 
 
Chromosomal common fragile sites are specific 
mammalian genomic regions that show an in-
creased frequency of gaps and breaks when 
cells are exposed to replication stress in vitro 
[36, 37]. Fragile sites are often involved in dele-
tions and translocations. The two most active 
fragile sites in the human genome are FRA3B 
and FRA16D, respectively, where the TSGs FHIT 
and WWOX are located on chromosomes 3 and 
16, respectively. The FHIT gene, which maps to 
the chromosomal region of FRA3B is frequently 
deleted, or involved in translocation breakpoints 
in a large number of tumour types [38-41]. Like 
FHIT, WWOX is also downregulated in many hu-
man cancers, including prostate cancer [42]. 
From our array data we can see that in four 
Figure 6. Schematic representation 
of chromosome 4 and 6 material in 
LNCaP cells. A. Two normal chromo-
some 4 and two der(4)t(4;6;10)
(q22.3::q25.3q15::q23.33). The 
chromosome 4 and 6 breakpoints 
are indicated by the arrows. B. One 
der(6)t(6;16)(p21.1::q22.2) and two 
der(6)t(4;6)(q22.3::q15). The chro-
mosome 4 and 6 breakpoints are 
indicated by arrows. C. Two der(10)t
(6;10)(q25.3::q23.33). The chromo-
some 6 breakpoint is indicated by 
the arrows. D. Two der(16)t(6;16)
(p21.1::q22.2). The chromosome 6 
breakpoint is indicated by the arrow.  
 
Chromosome rearrangement inactivated tumour suppressor genes  
 
 
614                                                                                                            Am J Cancer Res 2011;1(5):604-617 
cases, breakpoints can be found within the 
WWOX gene. However, no chromosome break-
points were found within FHIT. The reduced ex-
pression of the WWOX gene in the majority 
(8/9) of paired samples indicated that WWOX 
may be commonly inactivated in prostate can-
cer. In one case, where a genomic breakpoint in 
WWOX was detected by SNP array analysis, 
WWOX expression level was higher in the tu-
mour sample than its matched normal control. 
In rare cases, new oncogenic proteins may be 
formed by fusion with a TSG. For example the 
PAX5 and ETV6 TSGs have oncogenic properties 
when found as part of a fusion gene [19]. The 
mechanism leading to over-expression of WWOX 
in this cancer sample should be further ana-
lysed.  
 
From our analysis of the recurrent breakpoints 
in prostate cancer, and the genes associated 
with them, it is clear that there are more 
known/putative TSGs residing at breakpoints 
than known/putative oncogenes. A number of 
well-characterised TSGs, including p53, PTEN, 
BRCA1 and BRCA2, were found at recurrent 
copy number change breakpoints. However, 
other well-known TSGs, such as RB, WT1, NF1, 
NF2, APC, CDH1 and VHL were not identified 
with recurrent breakpoints, indicating that the 
TSGs identified may be specifically targeted in 
prostate cancer.  
 
Using M-FISH, we have previously identified sev-
eral chromosomal alterations in the LNCaP cell 
line, including a complex t(4;6) translocation, 
which we have mapped in detail [24, 43]. FISH 
analysis of patient samples on tissue microar-
rays confirmed that t(4;6)(q22;q15) is a recur-
rent chromosomal translocation in prostate can-
cer [44]. A single gene, UNC5C, is interrupted by 
the t(4;6) breakpoints, leading to loss of the 
UNC5C promoter and exon 1 [24]. From our 
array data, and further FISH analysis, we can 
now reveal that, in LNCaP, 4q22 is fused to 
6q25.3 but not 6q15 in the derivative chromo-
some 4. Together with our previous findings, we 
can now fully interpret the fusion events involv-
ing chromosome 4 and 6 in LNCaP cell line 
(Figure 6).  
 
Among the five breakpoints on chromosome 6 
and two breakpoints on chromosome 4, only 3 
of them have been identified with known genes. 
The fusion gene tpc/hpr, caused by t(6;16), has 
been reported many years ago [45], but has not 
been identified as a recurrent fusion gene. The 
remaining two genes are SNX9 and UNC5C. 
Although our data showed that SNX9 and 
UNC5C are genomically fused together in the 
same gene orientation as a consequence of the 
4q22.3:6q25.3 chromosome recombination, no 
fusion transcript of SNX9:UNC5C can be de-
tected. UNC5C has been suggested to be a TSG 
[46, 47] and our QRT-PCR gene expression data 
supports this TSG role in prostate cancer. The 
reduced expression of SNX9 in cancer samples 
compared with their matched normal controls 
suggests that SNX9 may also has a potential 
TSG role. Therefore, the genomic fusion of 
SNX9:UNC5C in LNCaP cells may lead to the 
disruption of the activity of two TSGs. 
 
This study reveals that many TSGs are recur-
rently affected by genomic rearrangements. 
Their potential to be developed as cancer prog-
nostic markers or therapeutic targets should be 
further investigated. This finding will signifi-
cantly enhance our understanding of the ge-
netic alterations of prostate cancer, which will 
consequently improve the strategies for pros-
tate cancer treatment/management. We specu-
late that by using this microarray analysis ap-
proach to investigate other cancers we would 
also identify many TSGs at recurrent chromoso-
mal breakpoints. Using an array approach to 
identify genes affected by genomic breakpoints 
is not without its limitations; 1) it is not possible 
to identify whether truncated genes are fused to 
other genes 2) only genes at breakpoints asso-
ciated with copy number changes can be identi-
fied. Balanced translocations and other rear-
rangements that do not result in genomic copy 
number changes cannot be detected. However, 
a limited number of truly balanced rearrange-
ments exist in solid tumours [17]. Next genera-
tion sequencing of the cancer genome will fully 
reveal the features and consequence of ge-
nomic rearrangements. 
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